Investor Alert: Pomerantz Law Firm Investigates EyePoint, Inc.
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by EyePoint, Inc. (NASDAQ: EYPT) and its officers following a significant drop in the company's stock price after it announced negative results from its Phase 3 clinical trial for DURAVYU™. On August 17, 2026, EyePoint reported that the topline data from the LUGANO trial did not meet expectations compared to Regeneron Pharmaceuticals' Eylea. This led to a sharp decline in EyePoint's stock price by $9.88 per share (or 66.98%) on the same day. Pomerantz LLP, known for its work in securities class actions and corporate misconduct cases, is seeking investors who may be interested in joining an investigation or potential class action lawsuit.
